GLP1R and peripheral arterial disease: The ESC 2024 guidelines recommend the use of GLP-1 RAs and SGLT2is in patients with T2DM and PAD to reduce cardiovascular events, regardless of HbA1c levels or concurrent glucose-lowering therapy [9].